Ember Therapeutics Stock Net Income
| EMBT Stock | USD 0.0001 0.00 0.00% |
Ember Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from Ember Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Ember Therapeutics' valuation are summarized below:Ember Therapeutics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Ember |
Ember Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ember Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ember Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Ember Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Ember Therapeutics or generate 0.0% return on investment in Ember Therapeutics over 90 days. Ember Therapeutics is related to or competes with Medigene, Vaccinex, and Biomind Labs. Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company More
Ember Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ember Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ember Therapeutics upside and downside potential and time the market with a certain degree of confidence.
Ember Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ember Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ember Therapeutics' standard deviation. In reality, there are many statistical measures that can use Ember Therapeutics historical prices to predict the future Ember Therapeutics' volatility.Ember Therapeutics Backtested Returns
We have found three technical indicators for Ember Therapeutics, which you can use to evaluate the volatility of the firm. The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Ember Therapeutics are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Ember Therapeutics has perfect predictability. Overlapping area represents the amount of predictability between Ember Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ember Therapeutics price movement. The serial correlation of 1.0 indicates that 100.0% of current Ember Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Ember Therapeutics reported net income of (23,242). This is 100.01% lower than that of the sector and 100.03% lower than that of the Net Income industry. The net income for all United States stocks is 100.0% higher than that of the company.
Ember Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ember Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Ember Therapeutics could also be used in its relative valuation, which is a method of valuing Ember Therapeutics by comparing valuation metrics of similar companies.Ember Therapeutics is currently under evaluation in net income category among its peers.
Ember Fundamentals
| Current Valuation | 12 M | |||
| Shares Outstanding | 40 M | |||
| Shares Owned By Insiders | 65.00 % | |||
| Price To Earning | 26.61 X | |||
| EBITDA | 9.4 M | |||
| Net Income | (23.24 K) | |||
| Cash And Equivalents | 71.22 M | |||
| Cash Per Share | 0.41 X | |||
| Total Debt | 75 K | |||
| Debt To Equity | 0.33 % | |||
| Current Ratio | 3.32 X | |||
| Book Value Per Share | (0.74) X | |||
| Cash Flow From Operations | (16.72 K) | |||
| Beta | 3.33 | |||
| Market Capitalization | 926.88 K | |||
| Total Asset | 184 | |||
| Retained Earnings | 289 K | |||
| Working Capital | 58.61 M | |||
| Current Asset | 83.91 M | |||
| Current Liabilities | 25.3 M | |||
| Net Asset | 184 |
About Ember Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ember Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ember Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ember Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ember Pink Sheet Analysis
When running Ember Therapeutics' price analysis, check to measure Ember Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ember Therapeutics is operating at the current time. Most of Ember Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ember Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ember Therapeutics' price. Additionally, you may evaluate how the addition of Ember Therapeutics to your portfolios can decrease your overall portfolio volatility.